Connect your AI

Upstream Bio, Inc. UPB Increase (Decrease) in Accounts and Notes Receivable

Increase (Decrease) in Accounts and Notes Receivable at other companies

PepsiCoPEP

$530M+66.7%

Garrett Motion Inc.GTX

$112M+100%

Simon Property GroupSPG

-$57.42M-63.6%

CignaCI

-$2.15B-198%

MGP IngredientsMGPI

-$29.44M+27.5%

PaccarPCAR

$279.1M+20.9%

Other financials

Income statement

Revenue$1.0M+82.7%

Operating income-$43.6M-36.2%

Net income-$40.6M-48.8%

EPS (diluted)-$0.75-47.1%

Balance sheet

Cash & equivalents$96.7M+35.6%

Total debt$1.1M-34.5%

Total equity$304.0M-31.8%

Total assets$318.1M-30.3%

Cash flow

Operating cash flow-$47.9M-16.2%

CapEx$54.0K-70.8%

Free cash flow-$30.7M-55.0%

Valuation

Market cap$346.11M-40.9%

Enterprise value$250.5M-51.4%

P/S104.2×-151×

Profitability

Operating margin-5,176.5%+1,764pp

Net margin-4,719%+2,752pp

Returns & leverage

Return on equity-41.8%—

Debt / equity0×0.0×

Current ratio23.1×-24.3×

Where this comes from

Reported directly by Upstream Bio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsAndNotesReceivable.

The official record: Upstream Bio, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Upstream Bio, Inc.'s increase (decrease) in accounts and notes receivable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Upstream Bio, Inc.'s increase (decrease) in accounts and notes receivable?: Upstream Bio, Inc. (UPB) reported increase (decrease) in accounts and notes receivable of $366K in Q1 2026.
How has Upstream Bio, Inc.'s increase (decrease) in accounts and notes receivable changed year-over-year?: Upstream Bio, Inc.'s increase (decrease) in accounts and notes receivable increased by 878.7% year-over-year, from -$47K to $366K.